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Conclusions: This subgroup analysis conﬁrms that erlotinib is an ac-
tive and safe therapy when used as third or successive line of treatment 
in patients with advanced or metastatic disease. In the multivariate 
analysis never smoking history is the most signiﬁcant predictive factor 
for longer TTP and OS.
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Background: Erlotinib, an oral HER-1/EGFR TKI is approved for 
patients with locally advanced or metastatic NSCLC after failure of 
at least one prior chemotherapy regimen. Erlotinib showed beneﬁt in 
terms of response rate, time to progression, and overall survival in a 
randomized, placebo-controlled trial. Although exploratory analysis 
demonstrated that the clinical beneﬁt of erlotinib was observed across 
most patient subgroups, this beneﬁt seemed to be greater in certain 
patients groups. Some authors have recommended considering salvage 
chemotherapy in the 2nd line setting instead of erlotinib for those 
patients with a good performance status. The purpose of the analysis 
we present here is to describe clinical outcome in the group of patients 
with NSCLC who presented with good PS (0–1)
Methods: The TargeT trial was an open-label, multicenter, non-ran-
domized phase II clinical trial carried out in 103 Spanish institutions. 
Patients with histologically conﬁrmed stage IIIB or IV NSCLC who 
had received treatment with chemotherapy in second or third line as 
well as chemotherapy-naïve patients non suitable for ﬁrst line conven-
tional chemotherapy were eligible. Eligibility criteria were: ≥18 years 
old, ECOG 0–2, adequate bone marrow, hepatic and renal function and 
written informed consent. Male patients receiving erlotinib 150 mg/day 
p.o until disease progression or withdrawal were the subject of this 
analysis. 
Results: From April 2004 to March 2006, 1,796 patients were included 
in the TargeT trial, of those 1,153 (64%) presented with performance 
status ECOG 0–1 at the beginning of the treatment with erlotinib, be-
ing the subject of this analysis. Main baseline characteristics: median 
age 64 years (range 26-89); 71% were male and 78% active or former 
smokers; histology: 53% adenocarcinoma (including BAC), 26% squa-
mous; 15% large cell carcinoma; 7% other; 82% had metastatic disease. 
Percentage of patients receiving erlotinib in 1st/2nd/3rd or further lines 
was: 27/40/33.
Among 731 patients with evaluable disease, treatment with erlotinib 
yielded an overall response rate (RR) of 19% and 39% of stabiliza-
tion of disease, for an overall control disease rate of 58%. Higher RRs 
were associated with female gender (36%; p<0.0001), non-smoking 
history (41%; p<0.0001), adenocarcinoma histology (26%; p<0.0001) 
and treatment with erlotinib in the ﬁrst line setting (33%; p<0.0001), in 
the univariate analysis. Similar associations were detected in terms of 
disease control ratio (60–70% in all subsets).
In the ITT population, median TTP was 4.1 months [95% CI 3.6–4.5] 
and median overall survival was 7.2 months (95% CI 6.5–7.8). Treat-
ment with erlotinib in chemo-naïve patients and the absence of smok-
ing habits were predictive factors for both a longer TTP and overall 
survival in the multivariate analysis. It deserves a mention that the 
subgroup of patients treated with erlotinib in the ﬁrst line setting (59% 
men; 76% stage IV; 63% non-smokers) reached a median OS of 9.4 
months (95% CI: 7.6–12.0), whilst non-smokers (79% treated in 2nd, 
3rd or further lines) showed a median OS of 13.4 months (95% CI: 
10.0–16.7).
Treatment with erlotinib was well tolerated and non unexpected toxici-
ties were reported. Skin rash and diarrhoea were the most common 
reported toxicities.
Conclusions: Erlotinib is active and well tolerated in patients with 
good performance status. Indirect comparisons suggest meaningful 
beneﬁt of erlotinib in patients with PS ECOG 0–1. On the basis of 
these results, there is no rational to delay the treatment with erlotinib in 
patients with good performance status, therefore potential candidates to 
receive conventional chemotherapy.
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Background: Erlotinib, an EGFR tyrosine kinase inhibitor, is a new 
second-line therapeutic option for patients with NSCLC. Erlotinib has 
been shown to achieve comparable improvement in overall survival, 
but with a more favourable side effect proﬁle than standard chemo-
therapy regimens. Another advantage of this agent is the use of oral 
administration. The favourable tolerability proﬁle of erlotinib may be 
beneﬁcial to the patients’ quality of life, and may lead to cost-savings 
for the health care system. The objective of this study was to evaluate 
the costs of treatment per patient in Germany for erlotinib, docetaxel 
and pemetrexed, taking into account the costs of managing adverse 
events (AEs).
Methods: The treatment regimens considered were continuous 
daily dosing with erlotinib (150mg/day, p.o.), and a 21-day cycle of 
docetaxel (75mg/m2 i.v.) or pemetrexed (500mg/m2 i.v.). Base costs 
and total costs per patient per quarter were calculated for the three 
regimens. The base costs comprised the outpatient costs for medical 
surveillance, drugs and drug administration, disregarding the costs of 
managing AEs. Costs of co-medications (dexamethasone for patients 
treated with docetaxel; dexamethasone, folic acid and vitamin B12 for 
patients treated with pemetrexed) were also considered. Total costs 
included the base costs plus, for each regimen, the average cost per 
patient of treating AEs in outpatient and inpatient facilities (only grade 
3/4 AEs (NCIC-CTC) were considered). Resource utilisation data were 
obtained from two multinational, randomized phase III trials in patients 
